{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:22:43Z","timestamp":1789611763137,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multidrug-resistant Acinetobacter baumannii remains challenging to treat. Although eravacycline has in vitro activity against this pathogen, there are no studies evaluating outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR) A. baumannii pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of adults hospitalized for pneumonia with DTR A. baumannii. Patients receiving eravacycline were compared with those receiving best previously available therapy. The primary outcome was 30-day in-hospital mortality. Secondary outcomes included clinical cure at Day 14, hospital and intensive care unit (ICU) length of stay, microbiologic cure, and readmission within 90 days with a positive A. baumannii respiratory culture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-three patients were included, with 27 receiving eravacycline. Eravacycline was associated with higher 30-day mortality (33% vs 15%; P = 0.048), lower microbiologic cure (17% vs 59%; P = 0.004), and longer durations of mechanical ventilation (10.5 vs 6.5 days; P = 0.016). At baseline, eravacycline patients had more A. baumannii bacteremia and coinfection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Among bacteremic patients, all 4 receiving eravacycline died by Day 30 and both patients receiving best previously available therapy survived. Upon exclusion of patients with bacteremia and SARS-CoV-2, there were no differences between the groups across any outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eravacycline-based combination therapy had similar outcomes to best previously available combination therapy for adults with DTR A. baumannii pneumonia. However, eravacycline should be used with caution in the setting of bacteremia as outcomes were poor in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221085551","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T11:39:09Z","timestamp":1651750749000},"page":"1299-1307","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy of Eravacycline\n                    <i>Versus<\/i>\n                    Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR)\n                    <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1177","volume":"56","author":[{"given":"Courtney J.","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Valley Hospital Medical Center, Las Vegas, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henderson Hospital, Henderson, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Jayakumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Valley Hospital Medical Center, Las Vegas, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogen","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-7507","authenticated-orcid":false,"given":"Velliyur","family":"Viswesh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Roseman University of Health Sciences, Henderson, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"bibr1-10600280221085551","unstructured":"Antibiotic resistance threats in the United States. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2019."},{"key":"bibr2-10600280221085551","volume-title":"Prioritization of Pathogens to Guide Discovery, Research, and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis","author":"World Health Organization","year":"2017"},{"key":"bibr3-10600280221085551","doi-asserted-by":"publisher","DOI":"10.3201\/eid1301.060716."},{"key":"bibr4-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199909000-00015."},{"key":"bibr5-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.13.1080.31597."},{"key":"bibr6-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1648-8."},{"key":"bibr7-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1186\/cc4869."},{"key":"bibr8-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1086\/517954."},{"key":"bibr9-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0371-8."},{"key":"bibr10-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199511000-00004."},{"key":"bibr11-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2020.450."},{"key":"bibr12-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-18."},{"key":"bibr13-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.09.012."},{"key":"bibr14-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1916-6."},{"key":"bibr15-10600280221085551","unstructured":"Xerava\n                      TM\n                      . Watertown, MA: Tetraphase Pharmaceuticals Inc.; 2018."},{"key":"bibr16-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-19."},{"key":"bibr17-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16."},{"key":"bibr18-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4093-1."},{"key":"bibr19-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013."},{"key":"bibr20-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378."},{"key":"bibr21-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST."},{"key":"bibr22-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST."},{"key":"bibr23-10600280221085551","unstructured":"National Healthcare Safety Network. Pneumonia (ventilator-associated [VAP] and non-ventilator-associated pneumonia [PNEU]) event. Centers for Disease Control and Prevention; January 2021. Accessed June 4, 2021. https:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/6pscVAPcurrent.pdf."},{"key":"bibr24-10600280221085551","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing, Thirty-First Informational Supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2021"},{"key":"bibr25-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04987-14."},{"key":"bibr26-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270."},{"key":"bibr27-10600280221085551","unstructured":"FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. September 1; 2010. Accessed March 5, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics."},{"key":"bibr28-10600280221085551","unstructured":"Tygacil (tigecycline) full prescribing information. Philadelphia, PA: Pfizer Inc. Accessed February 17, 2022. https:\/\/www.pfizermedicalinformation.com\/en-us\/tygacil\/dosage-admin."},{"key":"bibr29-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9."},{"key":"bibr30-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1013."},{"key":"bibr31-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00351-0."},{"key":"bibr32-10600280221085551","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221085551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221085551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221085551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:48Z","timestamp":1777375008000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221085551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10600280221085551"],"URL":"https:\/\/doi.org\/10.1177\/10600280221085551","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}